Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
July 13 2021 - 8:15AM
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
(“Brooklyn”), a biopharmaceutical company focused on exploring the
role that cytokine and gene editing/cell therapy can have in
treating patients with cancer, blood disorders, and monogenic
diseases, today announced the appointment of Jay Sial as its Chief
Administrative Officer, effective July 15, 2021.
“Jay has a long and impressive history managing
the finances of multiple health systems and hospitals and leading
the financial transformation of complex organizations through
prudent management and strategic activities, including fundraising,
business development and facilities management. We are truly
fortunate to have him join the team at Brooklyn
ImmunoTherapeutics,” commented Howard J. Federoff, M.D., Ph.D.,
Brooklyn’s Chief Executive Officer and President.
“I am honored to be joining Brooklyn
Immunotherapeutics which is using cutting edge mRNA based gene
editing and cellular reprogramming tools and look forward to
helping the team bring these therapies to cancer patients,” said
Mr. Sial regarding his new role with Brooklyn.
Prior to joining Brooklyn, Mr. Sial served as
Chief Financial Officer at Aspen Neurosciences, a privately-held
emerging biotechnology company. Before that he served as Chief
Financial Officer at multiple complex organizations, including
University of California Irvine Health, Trinity Health/Loyola
University Health System and University of Kentucky Healthcare. He
also served in key financial and management roles at Thomas
Jefferson University Hospital and FHP, Inc., a health maintenance
organization (HMO) based in Fountain Valley, California. He holds a
Master’s of Business Administration (Finance) from Virginia Tech
and a Bachelor of Arts degree in Economics and Accounting from
University of Delhi, India.
About Brooklyn
ImmunoTherapeuticsBrooklyn is focused on exploring the
role that cytokine-based therapy can have in treating patients with
cancer, both as a single agent and in combination with other
anti-cancer therapies. The company is also exploring opportunities
to advance therapies using leading edge gene editing/cell therapy
technology through its option agreement with Factor
Bioscience/Novellus Therapeutics.
Brooklyn’s most advanced program is studying the
safety and efficacy of IRX-2 in patients with head and neck cancer.
In a Phase 2A clinical trial in head and neck cancer, IRX-2
demonstrated an overall survival benefit. Additional studies are
either underway or planned in other solid tumor cancer
indications.
For more information about Brooklyn and its
clinical programs, please visit www.BrooklynITx.com.
Investor Relations Contact:CORE
IR516-222-2560investors@brooklynitx.com
Media Contact:Jules AbrahamCORE
IR917-885-7378julesa@coreir.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024